“We saw the strongest immune response in the 10 participants who received two doses of the vaccine, indicating that this might be a good strategy for vaccination,” Andrew Pollard, from the Oxford research group, said in the release.
The vaccine is being produced by pharmaceutical giant Astra Zeneca.
“We are encouraged by the Phase I/II interim data showing AZD1222 was capable of generating a rapid antibody and T-cell response against SARS-CoV-2. While there is more work to be done, today’s data increases our confidence that the vaccine will work and allows us to continue our plans to manufacture the vaccine at scale for broad and equitable access around the world,” stated Mene Pangalos, with AstraZeneca, in the release.
Astra Zeneca said it has signed agreements with governments around the world to supply the vaccine should it prove effective and gain regulatory approval. The company has said it will not seek to profit from the vaccine during the pandemic.
The new trial included 1,077 healthy adults aged 18 to 55 years with no history of COVID-19.
UK Prime Minister Boris Johnson welcomed the early results from the Oxford trial.